Aclaris Eyes Breakout on Upcoming Clinical Results
AI Prediction of Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, shows potential for significant stock price movement due to its focused development on novel drug candidates for immuno-inflammatory diseases. The recent inclusion in the Russell 2000 and 3000 indexes, alongside promising clinical trial advancements for its key drug candidates, positions ACRS as a potentially attractive investment opportunity.
ACRS Report Information
Prediction Date2025-07-03
Close @ Prediction$1.44
Mkt Cap545m
IPO DateN/a
AI-derived Information
Recent News for ACRS
- Apr 8, 8:30 am — Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference (GlobeNewswire)
- Mar 27, 10:10 am — Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 (GlobeNewswire)
- Mar 20, 11:00 am — Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
- Mar 18, 6:55 am — Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis (GlobeNewswire)
- Mar 3, 7:00 am — Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
- Feb 26, 10:59 am — Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference (MarketBeat)
- Feb 26, 9:45 am — Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
- Feb 26, 7:09 am — Aclaris: Q4 Earnings Snapshot (Associated Press Finance)
- Feb 26, 6:58 am — Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
- Feb 25, 12:15 pm — Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
- Feb 24, 9:55 pm — Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates (Zacks)
- Feb 24, 7:00 am — Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052 (GlobeNewswire)
NDAPR (News-Driven AI Prediction Revision) events for ACRS
-
Jan 13, 7:51 amRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: The initiation of the Phase 1b trial aligns with Aclaris's strategic focus on immuno-inflammatory diseases.
-
Jan 12, 7:03 amRevision: NO_CHANGE | Price Dir: YES_UP | Thesis: ACTIVE | Reason:Rationale: Positive trial initiation enhances Aclaris's clinical pipeline, potentially boosting investor confidence and stock value.
-
Jan 6, 1:03 pmRevision: NO_CHANGE | Price Dir: YES_UP | Thesis: ACTIVE | Reason:Rationale: Positive trial results enhance confidence in ATI-052's clinical advancement.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.